RWE Innovation Forum & Case Studies from Pfizer, Baxter, and BCBS on Real-World Evidence. Will you be there? Join our futuristic and free (yes, FREE) 1st Virtual HEOR Conference: “Real World Evidence Virtual Summit: Practical Strategies for Addressing the Needs of Multiple Stakeholders”, December 11, 2014, 8am-5pm ET. Register today!
Wish you employed better HEOR writers? Wish you were better at it? Join for HealthEconomics.Com’s “HEOR & Market Access Writing Workshop: 1st Annual Summit” for both HEOR execs and aspiring HEOR med writers in industry, agencies, and consulting companies. March 26-27, 2015, Philadelphia. Learn more.
|IN THIS ISSUE|
|SPOTLIGHT 1 OF THE WEEK||SPOTLIGHT 2 OF THE WEEK|
|New Journal Targets Real-World Data, Health Outcomes, Healthcare Decision-Making and Big Data.|
Drugs-Real World Outcomes is a new journal that targets research involving the use of real-world data to evaluate health outcomes and inform healthcare decision-making, with a particular focus on healthcare-related ‘big data’. (Source: Dene Peters, Anton Rensburg, Adis).
The ‘Assessing the Evidence for Health Care Decision Makers’ is an interactive questionnaire for users of evidence to assess health care research studies used in health technology assessments and/or drug formulary decisions. (Source: Assessing the Evidence).
How much profit does a pharmaceutical company need to drive innovation? What we’re seeing now is that instead of using profits to develop new drugs for diseases that currently have little or no treatment, pharmaceutical companies are all racing against each other, developing drugs for diseases that already have treatments. Do we really need five different drugs to treat the same disease, in the same way? (Source: Matthew Herper, Forbes, 10/23/14).
NICE considered six questions on value based assessment, and received 900 responses from industry, patient groups, academics, clinical organizations and the English Department of Health. (Source: James Raftery, the bmj, 10/22/14).
The Medicare Prescription Drug, Improvement, and Modernization Act was passed in 2003 with the intent to slow the spiraling costs of drugs to treat Medicare patients, but it has had no meaningful impact on cancer chemotherapy drug costs – in fact, the cost of cancer care has skyrocketed. (Source: Kathy Boltz, OncologyNurseAdvisor, 10/22/14).
Which of the following disease conditions has received the highest percentage of positive NICE decisions? Breast Cancer, Kidney Cancer, Multiple Myeloma. What would your guess be? The answer might surprise you. (Source: ContextMatters, 10/23/14).
As access and reimbursement becomes more complex in Europe, pharmaceutical manufacturers’ Medical Affairs (MA) organizations have a more important role to play. This paper examines that role and illuminates some of the unique factors manufacturers should bear in mind when developing an MA launch readiness plan in Europe for the first time. (Source: Campbell Alliance).
ACOs must accomplish three goals: reduce costs, increase efficiency and improve care quality. Learn how payer-led ACOs can achieve this triple aim and find success. (Source: FierceHealthPayer, 10/23/14).
The Green Park Collaborative recently released the Recommendations for Late Phase Drug Studies in Type 2 Diabetes Effectiveness Guidance Document (EGD), providing guidance for improving the design, conduct, and reporting of these studies. The recommendations cover four major areas: population, outcomes, methods and reporting for patient stakeholders. (Source: CMTP).
James T. Kenney, RPh, MBA, was recently interviewed by First Report Managed Care, where he discussed changes related to pharmaceutical coverage, reimbursement, and formularies in the face of the ever-changing climate of healthcare. Hear Dr. Kenney’s take on current events. (Source: First Report Managed Care, 10/20/14).
Recently released research from the UC Berkeley, looks at hospital ownership of physician groups in California, and the overall impact on healthcare costs. How much did the costs increase? (Source: Chad Terhune, Los Angeles Times, 10/21/14).
Listen to Dr Patti Peeples discuss the history of health economics and the ethical dilemmas of pricing pharmaceuticals, in this podcast from Relentless Health Value. (Source: relentlesshealthvalue, 10/16/14).
|Link of the Week||Conference of the Week||Webinar of the Week|